Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

PAS-004

Small molecule · Inhibitor of MEK1 (MAP2K1) and MEK2 (MAP2K2) · developed by Pasithea Therapeutics

Phase 1 Most advanced trial

KTTA Developer

1 Registered trials

What is PAS-004?

PAS-004 is a MEK1/2 inhibitor presented as oral capsules for once-daily administration. It is being studied in advanced solid tumors with RAS, NF1, or RAF mutations.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: MEK1 (MAP2K1), MEK2 (MAP2K2)
Mechanism: Inhibitor of MEK1 (MAP2K1) and MEK2 (MAP2K2)
Pathways: MAPK/ERK
Therapy area: Oncology
Developer: Pasithea Therapeutics Corp. (KTTA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06299839	Phase 1	RAS Mutation	Recruiting	KTTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsNF1 MutationRAF MutationRAS Mutation

Other drugs acting on MAP2K1 / MAP2K2

Mirdametinib FDA approved Trametinib FDA approved Atebimetinib Phase 3 IMM-6-415 Phase 1/2

Sources

ClinicalTrials.gov NCT06299839

Updated Oct 3, 2026. Something wrong or missing? Report it on the KTTA page.

Follow KTTA, the company behind PAS-004

See KTTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KTTA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z